Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anova Begins Phase 1/2a DB107 Trial for High-Grade Gliomas
Details : DB107 is an investigational gene therapy, which is currently being evaluated for the treatment of newly diagnosed high-grade glioma.
Product Name : DB107
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Vocimagene Amiretrorepvec,Fluocytosine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to accelerate the development of DZD9008 (sunvozertinib), an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity, for patients with EGFR Exon20ins mut...
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership